Literature DB >> 27692522

Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

José A Melero1, Vicente Mas2, Jason S McLellan3.   

Abstract

Extraordinary progress in the structure and immunobiology of the human respiratory syncytial virus glycoproteins has been accomplished during the last few years. Determination of the fusion (F) glycoprotein structure folded in either the prefusion or the postfusion conformation was an inspiring breakthrough not only to understand the structural changes associated with the membrane fusion process but additionally to appreciate the antigenic intricacies of the F protein. Furthermore, these developments have opened new avenues for structure-based designs of promising hRSV vaccine candidates. Finally, recent advances in our knowledge of the attachment (G) glycoprotein and its interaction with cell-surface receptors have revitalized interest in this molecule as a vaccine, as well as its role in hRSV immunobiology.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  RSV glycoproteins and vaccine development

Mesh:

Substances:

Year:  2016        PMID: 27692522      PMCID: PMC5189713          DOI: 10.1016/j.vaccine.2016.09.045

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  94 in total

1.  Antigenic structure of human respiratory syncytial virus fusion glycoprotein.

Authors:  J A López; R Bustos; C Orvell; M Berois; J Arbiza; B García-Barreno; J A Melero
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

2.  Structural homology of the central conserved region of the attachment protein G of respiratory syncytial virus with the fourth subdomain of 55-kDa tumor necrosis factor receptor.

Authors:  J P Langedijk; B L de Groot; H J Berendsen; J T van Oirschot
Journal:  Virology       Date:  1998-04-10       Impact factor: 3.616

3.  CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Authors:  Tatiana Chirkova; Songbai Lin; Antonius G P Oomens; Kelsey A Gaston; Seyhan Boyoglu-Barnum; Jia Meng; Christopher C Stobart; Calvin U Cotton; Tina V Hartert; Martin L Moore; Assem G Ziady; Larry J Anderson
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

4.  Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus.

Authors:  Sunee Techaarpornkul; Peter L Collins; Mark E Peeples
Journal:  Virology       Date:  2002-03-15       Impact factor: 3.616

5.  Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.

Authors:  Davide Corti; Siro Bianchi; Fabrizia Vanzetta; Andrea Minola; Laurent Perez; Gloria Agatic; Barbara Guarino; Chiara Silacci; Jessica Marcandalli; Benjamin J Marsland; Antonio Piralla; Elena Percivalle; Federica Sallusto; Fausto Baldanti; Antonio Lanzavecchia
Journal:  Nature       Date:  2013-08-18       Impact factor: 49.962

6.  Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G.

Authors:  S A Feldman; R M Hendry; J A Beeler
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.

Authors:  Margarita Magro; Vicente Mas; Keith Chappell; Mónica Vázquez; Olga Cano; Daniel Luque; María C Terrón; José A Melero; Concepción Palomo
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

8.  Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.

Authors:  Wenliang Zhang; Youngjoo Choi; Lia M Haynes; Jennifer L Harcourt; Larry J Anderson; Les P Jones; Ralph A Tripp
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

9.  The soluble form of human respiratory syncytial virus attachment protein differs from the membrane-bound form in its oligomeric state but is still capable of binding to cell surface proteoglycans.

Authors:  Estela Escribano-Romero; Joanna Rawling; Blanca García-Barreno; José A Melero
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism.

Authors:  Anders Krarup; Daphné Truan; Polina Furmanova-Hollenstein; Lies Bogaert; Pascale Bouchier; Ilona J M Bisschop; Myra N Widjojoatmodjo; Roland Zahn; Hanneke Schuitemaker; Jason S McLellan; Johannes P M Langedijk
Journal:  Nat Commun       Date:  2015-09-03       Impact factor: 14.919

View more
  26 in total

1.  Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.

Authors:  Kelsey A Brakel; Basavaraj Binjawadagi; Kristen French-Kim; Mauria Watts; Olivia Harder; Yuanmei Ma; Jianrong Li; Stefan Niewiesk
Journal:  Vaccine       Date:  2021-10-23       Impact factor: 3.641

2.  Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.

Authors:  Young-Man Kwon; Youri Lee; Ki Hye Kim; Yu Jin Jung; Zhuo Li; Subbiah Jeeva; Sujin Lee; Martin L Moore; Sang-Moo Kang
Journal:  Vaccine       Date:  2019-09-18       Impact factor: 3.641

Review 3.  Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.

Authors:  Prasad S Kulkarni; Julia L Hurwitz; Eric A F Simões; Pedro A Piedra
Journal:  Viral Immunol       Date:  2018-01-16       Impact factor: 2.257

4.  Respiratory syncytial virus genotypes NA1, ON1, and BA9 are prevalent in Thailand, 2012-2015.

Authors:  Ilada Thongpan; John Mauleekoonphairoj; Preeyaporn Vichiwattana; Sumeth Korkong; Rujipat Wasitthankasem; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PeerJ       Date:  2017-10-27       Impact factor: 2.984

Review 5.  Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection.

Authors:  Silvia Vandini; Carlotta Biagi; Marcello Lanari
Journal:  Int J Mol Sci       Date:  2017-08-06       Impact factor: 5.923

6.  Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.

Authors:  Harrison G Jones; Tina Ritschel; Gabriel Pascual; Just P J Brakenhoff; Elissa Keogh; Polina Furmanova-Hollenstein; Ellen Lanckacker; Jehangir S Wadia; Morgan S A Gilman; R Anthony Williamson; Dirk Roymans; Angélique B van 't Wout; Johannes P Langedijk; Jason S McLellan
Journal:  PLoS Pathog       Date:  2018-03-06       Impact factor: 6.823

7.  The Morphology and Assembly of Respiratory Syncytial Virus Revealed by Cryo-Electron Tomography.

Authors:  Zunlong Ke; Rebecca S Dillard; Tatiana Chirkova; Fredrick Leon; Christopher C Stobart; Cheri M Hampton; Joshua D Strauss; Devi Rajan; Christina A Rostad; Jeannette V Taylor; Hong Yi; Raven Shah; Mengtian Jin; Tina V Hartert; R Stokes Peebles; Barney S Graham; Martin L Moore; Larry J Anderson; Elizabeth R Wright
Journal:  Viruses       Date:  2018-08-20       Impact factor: 5.048

8.  RSV Takes Control of Neonatal Breg Cells: Two Hands on the Wheel.

Authors:  Peter J M Openshaw
Journal:  Immunity       Date:  2017-02-21       Impact factor: 43.474

9.  Induction of high titred, non-neutralising antibodies by self-adjuvanting peptide epitopes derived from the respiratory syncytial virus fusion protein.

Authors:  Noushin Jaberolansar; Keith J Chappell; Daniel Watterson; Imogen M Bermingham; Istvan Toth; Paul R Young; Mariusz Skwarczynski
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

10.  An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.

Authors:  Judith Falloon; Jing Yu; Mark T Esser; Tonya Villafana; Li Yu; Filip Dubovsky; Therese Takas; Myron J Levin; Ann R Falsey
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.